Combination of CIS inhibition with CTLA-4 and PD-1 blockade exerts even greater effects in reducing melanoma metastasis compared with either of these treatments administered alone; thus, CIS inhibition could offer an alternative therapeutic option for patients not responding to other immune checkpoint inhibitors [22]. The gene discussed is CTLA4; the disease is in situ carcinoma.